Impact of Cardiac Magnetic Resonance Imaging on Endothelial Function in Type 2 Diabetes

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02001753

Enrollment

Registered

2013-12-05

Start date

2013-12-31

Completion date

2014-02-28

Last updated

2014-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabetes

Brief summary

Magnetic resonance (MR) imaging is a widely used and well-established noninvasive medical diagnostic imaging tool. By using a static and a gradient magnetic field in combination with a radiofrequency field (RF), MR provides excellent contrast among different tissues of the body. Although long-term effects on human health from exposure to strong static magnetic fields seem unlikely, acute effects such as vertigo, nausea, change in blood pressure, reversible arrhythmia, and neurobehavioural effects have been documented from occupational exposition to 1.5 T. Cardiac MR (CMR) imaging requires some of the strongest and fastest switching electromagnetic gradients available in MR exposing the patients to the highest administered energy levels accepted by the controlling authorities. Studies focusing on experimental teratogenic or carcinogenic effects of MR revealed conflicting results. Since CMR is emerging as one of the fastest growing new fields of broad MR application, it is of particular concern that a recent in vitro study with CMR sequences has reported on CMR-induced DNA damages in white blood cells up to 24 h after exposure to 1.5 T CMR. Therefore, we hypothesized that CMR can induce the damage of endothelium and endothelial progenitor cells in type 2 diabetes

Interventions

DEVICECMR

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

HEALTH_SERVICES_RESEARCH

Masking

SINGLE (Subject)

Eligibility

Sex/Gender

MALE

Age

30 Years to 65 Years

Healthy volunteers

Yes

Inclusion criteria

* Male * Age 30 to 65 years old * Type 2 diabetes

Exclusion criteria

* Renal and liver function dysfunction * Heart failure * Malignancy * Patients with contraindications to cardiac magnetic resonance (CMR) * Patients with clinical detectable angiopathy

Design outcomes

Primary

Measure	Time frame	Description
Changes of endothelium-dependent arterial dilation before and after CMR in type 2 diabetes	3 days	The endothelium-dependent arterial dilation was measured at baseline, 1day, 2 day, 3 day after CMR.

Secondary

Measure	Time frame	Description
Changes of endothelial progenitor cells before and after CMR in peripheral blood	3 days	The numbers of endothelial progenitor cells was determined at baseline, 1 day, 2 day, 3 day after CMR.

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 18, 2026